17679729

Source:http://linkedlifedata.com/resource/pubmed/id/17679729

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0023467, umls-concept:C0042291, umls-concept:C0049065, umls-concept:C0205195, umls-concept:C0920321
pubmed:issue	25
pubmed:dateCreated	2007-8-31
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00079378
pubmed:abstractText	To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML).
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/K23CA120708, http://linkedlifedata.com/resource/pubmed/grant/R01 CA102031, http://linkedlifedata.com/resource/pubmed/grant/U01 CA 76576
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Azacitidine, http://linkedlifedata.com/resource/pubmed/chemical/Valproic Acid, http://linkedlifedata.com/resource/pubmed/chemical/decitabine
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1527-7755
pubmed:author	pubmed-author:BlumWilliamW, pubmed-author:ByrdJohn CJC, pubmed-author:ChanKenneth KKK, pubmed-author:DevineHollieH, pubmed-author:DevineSteven MSM, pubmed-author:GreverMichael RMR, pubmed-author:HackansonBjoernB, pubmed-author:HeeremaNyla ANA, pubmed-author:HuynhLenguyenL, pubmed-author:KefauverCherylC, pubmed-author:KlisovicRebecca BRB, pubmed-author:LiuShujunS, pubmed-author:LiuZhongfaZ, pubmed-author:LozanskiGerardG, pubmed-author:MarcucciGuidoG, pubmed-author:MurgoAnthonyA, pubmed-author:PlassChristophC, pubmed-author:VukosavljevicTamaraT
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	25
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	3884-91
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:17679729-Adult, pubmed-meshheading:17679729-Aged, pubmed-meshheading:17679729-Aged, 80 and over, pubmed-meshheading:17679729-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17679729-Azacitidine, pubmed-meshheading:17679729-Brain Diseases, pubmed-meshheading:17679729-Fatigue, pubmed-meshheading:17679729-Humans, pubmed-meshheading:17679729-Infection, pubmed-meshheading:17679729-Leukemia, Myeloid, Acute, pubmed-meshheading:17679729-Maximum Tolerated Dose, pubmed-meshheading:17679729-Middle Aged, pubmed-meshheading:17679729-Neutropenia, pubmed-meshheading:17679729-Remission Induction, pubmed-meshheading:17679729-Treatment Failure, pubmed-meshheading:17679729-Valproic Acid
pubmed:year	2007
pubmed:articleTitle	Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
pubmed:affiliation	Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA. william.blum@osumc.edu
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I, Research Support, N.I.H., Extramural